CAMP Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
1.9M
+6.7%
1.8M
+37.5%
1.3M
+271.8%
348.0K
-56.2%
795.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
1.9M
+6.7%
1.8M
+37.5%
1.3M
+271.8%
348.0K
-56.2%
795.0K
Operating Expenses
15.9M
+5.1%
15.2M
+5.5%
14.4M
+9.5%
13.1M
-9.2%
14.4M
R&D
11.4M
+5.7%
10.8M
+6.5%
10.2M
+21.6%
8.4M
-15.2%
9.8M
SG&A
4.5M
+3.5%
4.3M
+3.3%
4.2M
-11.8%
4.8M
+3.7%
4.6M
Operating Income
-14029000
-4.9%
-13380000
-2.4%
-13071000
-2.3%
-12776000
+6.4%
-13651000
EBITDA
-13506000
-5.0%
-12865000
-2.5%
-12551000
-1.2%
-12404000
+6.3%
-13235000
Net Income
-28956000
+13.6%
-33530000
-82.9%
-18331000
+54.5%
-40284000
-166.8%
-15099000
EPS (Basic)
$-0.37
+36.2%
$-0.58
-81.2%
$-0.32
+57.3%
$-0.75
-36.4%
$-0.55
EPS (Diluted)
$-0.37
+36.2%
$-0.58
-81.2%
$-0.32
+57.3%
$-0.75
-36.4%
$-0.55
Shares (Diluted)
78.9M
+36.3%
57.9M
+0.0%
57.9M
+7.4%
53.9M
+97.7%
27.3M
CAMP4 Therapeutics (CAMP) — Financials